Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Anlon HealthcareNSE:AHCL +2.39%20 EV-to-EBIT is 0.56 as of Aug. 08, 2026, which is 95% below its 10-year median of 11.57. GuruFocus rates NSE:AHCL with a GF Score™ of 20/100. The stock has 4 warning signs investors should review. Among 686 Drug Manufacturers companies, Anlon Healthcare ranks better than 96.94% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Anlon Healthcare's Enterprise Value for the quarter that ended in Jun. 2026 was ₹8,499 Mil.
Anlon Healthcare's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹14,850 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anlon Healthcare EV-to-EBIT Related Terms
Anlon Healthcare EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Anlon Healthcare's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Anlon Healthcare's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anlon Healthcare EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Anlon Healthcare's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Anlon Healthcare's EV-to-EBIT falls into.
Anlon Healthcare's current Enterprise Value is ₹8,372 Mil.
Anlon Healthcare's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹14,850 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anlon Healthcare (NSE:AHCL) has a EV-to-EBIT of 0.56 as of Aug. 08, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Anlon Healthcare and its competitors. This is 95% below median its historical median of 11.57. Over the past decade, Anlon Healthcare's EV-to-EBIT has ranged from 0.39 to 24.70. According to the industry distribution chart, Anlon Healthcare ranks #21 out of 686 companies in the Drug Manufacturers industry, placing it in the top 3.1%.
Is Anlon Healthcare's EV-to-EBIT too high?
Anlon Healthcare's current EV-to-EBIT of 0.56 is 95% below median its 10-year median of 11.57. Over the past 10 years, this metric has ranged from a low of 0.39 to a high of 24.70. The Drug Manufacturers industry median EV-to-EBIT is 15.73. Anlon Healthcare's value of 0.56 is 96.4% below this industry median. Based on the distribution chart, Anlon Healthcare ranks #21 out of 686 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Anlon Healthcare has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Anlon Healthcare's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Anlon Healthcare ranks #21 out of 686 companies for EV-to-EBIT. This places Anlon Healthcare in the top 3% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 15.73. Anlon Healthcare's value of 0.56 is 96.4% below this benchmark. Historically, Anlon Healthcare's own EV-to-EBIT has ranged from 0.39 to 24.70 over the past decade. While the company's 10-year median is 11.57 vs. the industry median of 15.73, Anlon Healthcare has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.73, based on 686 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anlon Healthcare's current EV-to-EBIT of 0.56 is 96.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Anlon Healthcare and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anlon Healthcare's current EV-to-EBIT is 0.56, which is 95% below median its own 10-year median of 11.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anlon Healthcare stock overvalued right now?
Anlon Healthcare (NSE:AHCL) has a current EV-to-EBIT of 0.56. The current EV-to-EBIT is 0.56, which is 95% below median its 10-year median of 11.57 and 96.4% below the Drug Manufacturers industry median of 15.73. Anlon Healthcare's overall GF Score™ is 20/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Anlon Healthcare (NSE:AHCL), the current EV-to-EBIT is 0.56 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anlon Healthcare Ltd is a chemical manufacturing company engaged in manufacturing of; (i) high purity advance pharmaceutical intermediates which serves as raw material/ key starting material in the manufacturing of active pharmaceutical ingredients; and (ii) active pharmaceutical ingredients which serves as a raw material for pharmaceutical formulations in preparation of various type of Finished Dosage Formula such as tablet, capsules, ointment, syrup etc, ingredients in nutraceuticals formulations, personal care products and animal health products. Its products spans across the family of pharmaceutical intermediates, active pharmaceutical ingredients, nutraceutical APIs and ingredients for personal care and veterinary API.
20GF Score
Get the complete analysis for NSE:AHCL
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AHCL has been successfully added to your 
